Drugs

, Volume 45, Issue 1, pp 15–28 | Cite as

Liposomes in Drug Delivery

Clinical, Diagnostic and Ophthalmic Potential
  • Gregory Gregoriadis
  • Alexander T. Florence
Review Article

Summary

Liposomes (phospholipid-based vesicles) have been investigated since 1970 as a system for the delivery or targeting of drugs to specific sites in the body. Because of their structural versatility in terms of size, composisition, surface charge, bilayer fluidity and ability to incorporate almost any drug regardless of solubility, or to carry on their surface cell-specific ligands, liposomes have the potential to be tailored in a variety of ways to ensure the production of formulations that are optimal for clinical use. This includes controlled retention of entrapped drugs in the presence of biological fluids, controlled vesicle residence in the blood circulation or other compartments in the body, and enhanced vesicle uptake by target cells.

Accumulated in vivo evidence, particularly in areas such as cancer chemotherapy, antimicrobial therapy, vaccines, diagnostic imaging and the treatment of ophthalmic disorders has indicated clearly that some liposome-entrapped drugs and vaccines exhibit superior pharmacological properties to those observed with conventional formulations. Such work has encouraged the application of liposomes in the treatment of diseases in humans. A large number of trials in patients with cancer or infections suggest that certain liposomal drug formulations are likely to prove clinically useful.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler-Moore JP, Chiang S-M, Satorius A, Guerra D, McAndrews B, et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). Journal of Antimicrobial Therapy 28 (Suppl. B): 63–71, 1991CrossRefGoogle Scholar
  2. Ahmed I, Patton TF. Importance of the non-corneal absorption route in topical ophthalmic drug delivery. Investigative Ophthalmology and Visual Science 26: 584–587, 1985PubMedGoogle Scholar
  3. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. Nature 252: 252, 1974PubMedCrossRefGoogle Scholar
  4. Alvarado JA. The use of a liposome encapsulated 5-fluoro-orotate for glaucoma surgery. 1. Animal studies. Transactions of the American Ophthalmology Society 87: 489–514, 1990Google Scholar
  5. Alving CR, Richards RL, Moss J, Alving LI, Clements JD, et al. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria antigen. Vaccine 4: 166–172, 1986PubMedCrossRefGoogle Scholar
  6. Bakker-Woudenberg IAJM, Lookerse AF, Roerdink, F, Regts D, Michel MF. Free versus liposome-entrapped ampicillin in treatment of infection due to Listeria monocytogenes in normal and athymic nude mice. Journal of Infectious Diseases 151: 917–924, 1985PubMedCrossRefGoogle Scholar
  7. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology 13: 238, 1965PubMedCrossRefGoogle Scholar
  8. Barsoum IS, Reich M. The effect of liposome-entrapped penicillin G on Staph. aureus infection in mice. Pharmacology 10: 358, 1982Google Scholar
  9. Benita S, Plenecassagne JD, Caves G, Drouin D, Dong PLH, et al. Pilocarpine hydrochloride liposomes: characterization in vitro and preliminary evaluation in vivo in rabbit eye. Journal of Microencapsulation 1: 203–216, 1984PubMedCrossRefGoogle Scholar
  10. Blume G, Cevc G. Liposomes for sustained drug release in vivo. Biochimica et Biophysica Acta 1029: 91–97, 1990PubMedCrossRefGoogle Scholar
  11. Bonventre P, Gregoriadis G. Killing of intraphagocytic Staph. aureus by dihydrostreptomycin entrapped in liposomes. Antimicrobial Agents and Chemotherapy 13: 1049–1051, 1978PubMedCrossRefGoogle Scholar
  12. Burnstein NL. Basic science of ocular pharmacology. In Bartlett & Joanus (Eds) Clinical ocular pharmacology, 2nd edn, Butterworths, Boston, 1989Google Scholar
  13. Caride VJ, Sostman HD, Twickler J, Zacharis H, Orphanoudakis SC, et al. Brominated radiopague liposomes: contrast agent for computed tomography of liver and spleen. A preliminary report. Investigative Radiology 17: 381–385, 1982PubMedCrossRefGoogle Scholar
  14. Caride VJ, Sostman RD, Winchell RJ, Gore JC. Relaxation enhancement using liposomes carrying paramagnetic species. Magnetic Resonance Imaging 2: 107–112, 1984PubMedCrossRefGoogle Scholar
  15. Chopra R, Blair S, Strong J, Cervi P, Patterson KG, et al. Liposomal amphotericin B (‘AmBisome’) in the treatment of fungal infections in neutropenic patients. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 93–104, 1991PubMedCrossRefGoogle Scholar
  16. Connor J, Huang L. Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive imnuno liposomes. Journal of Cell Biology 101: 582–589, 1985PubMedCrossRefGoogle Scholar
  17. Davidson RN, Croft SL, Scott A, Maini M, Moody AH, et al. Liposomal amphotericin in drug resistant visceral leishmaniasis. Lancet 337: 1061–1062, 1199CrossRefGoogle Scholar
  18. Dees C, Fountain MW, Taylor JR, Schultz RD. Enhanced intraphagocytic killing of Brucella abortus in bovine mononuclear cells by liposomes containing gentamycin. Vetinary Immunology Immunopathology 8: 171–182, 1985CrossRefGoogle Scholar
  19. Desiderio JV, Campbell SG. Intraphagocytic killing of Salmonella typhimurium by liposome-encapsulated cephalothin. Journal of Infectious Disease 148: 563–570, 1983CrossRefGoogle Scholar
  20. Duzgunes N, Perumal VK, Kesavalu L, Goldstein JA, Debs RJ, et al. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellular complex infection in beige mice. Antimicrobial Agents and Chemotherapy 32: 1404–1411, 1988PubMedCrossRefGoogle Scholar
  21. Fielding RM. Liposomal drug delivery: advantages and limitations from a clinical pharmacokinetic and therapeutic perspective. Clinical Pharmacokinetics 21: 155–164, 1991PubMedCrossRefGoogle Scholar
  22. Fishman P, Peyman GA, Hendricks R, Hui SL. Liposome-encapsulated 3H-5-FU in rabbits. International Ophthalmology 13: 361–365, 1989PubMedCrossRefGoogle Scholar
  23. Florence AT, Gregoriadis G. Targeting of peptides and proteins. Trends in Biotechnology 9: 295–297, 1991PubMedCrossRefGoogle Scholar
  24. Forssen E, Tokes Z. Use of amionic liposomes for the reduction of chronic doxorubicin-induced cardio-toxicity. Proceedings of the National Academy of Science 78: 1873–1877, 1981CrossRefGoogle Scholar
  25. Fries LF, Gordon DM, Richards RL, Egan JE, Hollingdale MR, et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proceedings of the National Academy of Science 89: 358–362, 1992CrossRefGoogle Scholar
  26. Gabizon A, Dagam A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carrier of adriamycin: reduced cardiac uptake and preserved antitumour activity in mice. Cancer Research 42: 4734–4739, 1982PubMedGoogle Scholar
  27. Gabizon A, Papahadjopoulos D. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochimica et Biophysica Acta 1103: 94–100, 1992PubMedCrossRefGoogle Scholar
  28. Gabizon A, Price DC, Huberty J, Breaslier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumours: biodistribution and imaging studies. Cancer Research 50: 6371–6378, 1990PubMedGoogle Scholar
  29. Garcon N, Gregoriadis G, Taylor M, Summerfield J. Targeted immunoadjuvant action of tetanus toxoid-containing liposomes coated with mannosylated albumin. Immunology 64: 743–745, 1988PubMedGoogle Scholar
  30. Gregoriadis G. The carrier potential of liposomes in biology and medicine. New England Journal of Medicine 295: 704–710, 1976PubMedCrossRefGoogle Scholar
  31. Gregoriadis G. The liposome drug carrier concept: its development and future. In Gregoriadis & Allison (Eds) Liposomes in biological systems, Academic Press, London, 1980Google Scholar
  32. Gregoriadis G (Ed.). Liposomes as drug carriers: recent trends and progress, John Wiley, Chichester, 1988aGoogle Scholar
  33. Gregoriadis G. Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo. In Gregoriadis (Ed.) Liposomes as drug carriers: recent trends and progress, John Wiley, Chichester, 1988bGoogle Scholar
  34. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunology Today 11: 89–97, 1990PubMedCrossRefGoogle Scholar
  35. Gregoriadis G. Overview of liposomes. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 39–48, 1991PubMedCrossRefGoogle Scholar
  36. Gregoriadis G (Ed). Liposome Technology, 2nd ed., CRC Press Inc, Boca Raton, 1993aGoogle Scholar
  37. Gregoriadis G. Liposomes as immunological adjuvants: approaches to immunopotentiation including ligand-mediated targeting to macrophages. Research in Immunology 143: 178–185, 245–246, 1992aPubMedCrossRefGoogle Scholar
  38. Gregoriadis G, Davis C. Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells. Biochemical and Biophysical Research Communications 89: 1287–1293, 1979PubMedCrossRefGoogle Scholar
  39. Gregoriadis G, Ryman B. Lysosomal localization of β-fructofur-anosidase-containing liposomes injected into rats. Some implications in the treatment of genetic disorders. Biochemical Journal 129: 123–133, 1972PubMedGoogle Scholar
  40. Gregoriadis G, Florence AT. Liposomes and cancer therapy. Cancer Cells 4: 144–146, 1991Google Scholar
  41. Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug carrier potential of liposomes in cancer chemotherapy. Lancet 1: 1313–1316, 1974PubMedCrossRefGoogle Scholar
  42. Gregoriadis G, Neerunjun DE, Hunt R. Fate of liposome-associated agent injected into normal and tumour-bearing rodents. Attempts to improve localization in tissues. Life Sciences 21: 357–370, 1977PubMedCrossRefGoogle Scholar
  43. Gregoriadis G, da Silva H, Florence AT. A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRV). International Journal of Pharmaceutics 65: 235–242, 1990CrossRefGoogle Scholar
  44. Gregoriadis G, Tan L, Ahmeida ETCS, Jennings R. Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 surface antiges. Vaccine 10: 747–753, 1992bPubMedCrossRefGoogle Scholar
  45. Gregoriadis G, Florence AT, Patel HM (Eds). Liposomes in drug delivery, Harwood, Chur, 1993bGoogle Scholar
  46. Guo LSS, Radhakrishnan R, Redmann CT. Adhesion of positively charged liposomes to mucosal tissues. Journal of Liposome Research 3: 319–337, 1989/1990CrossRefGoogle Scholar
  47. Harding CV, Collins D, Unanne ER. Processing of liposome-encapsulated antigens targeted to specific subcellular compartments. Research in Immunology 143: 188–191, 1992PubMedCrossRefGoogle Scholar
  48. Hirnle P. Histological findings in rabbit lymph nodes after endolymphatic injection of liposomes containing blue dye. Journal of Pharmacy and Pharmacology 43: 217–218, 1991PubMedCrossRefGoogle Scholar
  49. Huang L, Reddy R, Nair SK, Zhou F, Rouse B. Liposomal delivery of soluble protein antigens for class I MHC-mediated antigen presentation. Research in Immunology 143: 192–196, 1992PubMedCrossRefGoogle Scholar
  50. Janoff AS. Lipids, liposomes, rational drug design. Journal of Laboratory Investigation 66: 655–658, 1992Google Scholar
  51. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, et al. Unusual lipid structures selectively reduce the toxicity of Amphotericin B. Proceedings of the National Academy of Science 85: 6122–6126, 1988CrossRefGoogle Scholar
  52. Kabalka GW, Davis MA, Moss TH, Buonocore E, Hubner K, et al. Gadolinium-labelled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magnetic Resonance in Medicine 19: 406–415, 1991PubMedCrossRefGoogle Scholar
  53. Kan VL, Bennett JE, Amantea MA, Smolskis MC, McManus E, et al. Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. Journal of Infectious Disease 164: 418–421, 1991CrossRefGoogle Scholar
  54. Karlik S, Florio E, Grant CW. Comparative evaluation of two membrane-based liposomal MRI contrast agents. Magnetic Resonance in Medicine 19: 56–66, 1991PubMedCrossRefGoogle Scholar
  55. Kersten GFA, van de Put AM, Teerhlink T, Beuvery EC, Crommelin DJA. Infection and Immunity 56: 1661–1664, 1988PubMedGoogle Scholar
  56. Khoobehi B, Peyman GA, McTurnan WG, Niesman MR, Megin RL, et al. Externally triggered release of dyes and drugs from liposomes into the eye. An in vitro and in vivo study. Ophthalmology 95: 950–955, 1988PubMedGoogle Scholar
  57. Khoobehi B, Peyman GA, Niesman MR, Oncel M. Hyperthermia and temperature sensitive liposomes: selective delivery of drugs into the eye. Japanese Journal of Ophthalmology 33: 405–412, 1989PubMedGoogle Scholar
  58. Khoobehi B, Schuele KM, Ali OM, Peyman GA. Measurement of circulation time in the retinal vasculature using selective angiography. Ophthalmology 97: 1061–1070, 1990PubMedGoogle Scholar
  59. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vitro and in vivo. Biochemical Journal 186: 591–598, 1980PubMedGoogle Scholar
  60. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Letters 268: 235–237, 1990PubMedCrossRefGoogle Scholar
  61. Lee VHL, Takemoto, KA, Timoto DA, Precorneal factors influencing the ocular distribution of topically applied liposomal inulin. Current Eye Research 3: 585–591, 1984PubMedCrossRefGoogle Scholar
  62. Liu KR, Peyman GA, Khoobehi B. Efficacy of liposome-bound amphotericin B for the treatment of experimental fungal endophthalmitis in rabbits. Investigative Ophthalmology and Visual Science 30: 1527–1534, 1989PubMedGoogle Scholar
  63. Lee VHL, Urrea PT, Smith, RE, Schanzlin DJ. Ocular drug bioavailability from topically applied liposomes. Survey of Opthalmology 29: 335–348, 1985CrossRefGoogle Scholar
  64. Lopez-Berestein G, Bodey GP, Fronkel LS, Mehta K. Treatment of hepatosplenic candidiasis with liposomal amphotericin British Journal of Clinical Oncology 5: 310–317, 1987Google Scholar
  65. Lopez-Berestein G, Fidler I (Eds). Liposomes in the therapy of infectious diseases and cancer, Alan Liss, New York, 1989Google Scholar
  66. Lopez-Berestein G, Mehta R, Hopfer RL, Mill K, Kasi L, et al. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposomeencapsulated amphotericin. British Journal of Infectious Disease 147: 939–944, 1983CrossRefGoogle Scholar
  67. Manesis EK, Cameron CH, Gregoriadis G. Hepatitis B surface antigen-containing liposomes enhance humoural and cell-mediated immunity to the antigen. FEBS Letters 102: 107–111, 1979PubMedCrossRefGoogle Scholar
  68. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, et al. Influence of vesicle size, lipid composition and drug to lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Research 49: 5922–5930, 1989PubMedGoogle Scholar
  69. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, et al. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochimica et Biophysica Acta 1025: 143–151, 1990PubMedCrossRefGoogle Scholar
  70. McCalden TA, Levy M. Retention of topical liposomal formulations on the cornea. Experientia 46: 713–715, 1990PubMedCrossRefGoogle Scholar
  71. Megaw JM, Takei Y, Lerman S. Lectin-mediated binding of liposomes to the ocular lens. Experimental Eye Research 32: 395–405, 1981PubMedCrossRefGoogle Scholar
  72. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data form and phase II/III clinical trial. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 83–91, 1991PubMedCrossRefGoogle Scholar
  73. Mezei M. Liposomes in topical application of drugs: a review. In Gregoriadis (Ed.) Liposomes as drug carriers: recent trends and progress, Wiley, Chichester, 1988Google Scholar
  74. Ostro M (Ed.). Liposomes, Marcel Dekker Inc., New York, 1983Google Scholar
  75. New RRC, Chance ML, Heath J. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. Journal of Antimicrobial Chemotherapy 8: 371–381, 1981PubMedCrossRefGoogle Scholar
  76. Norley SG, Huang L, Rouse BT. Targeting of drug-loaded immunoliposomes to herpes simplex virus-infected corneal cells: an effective means of inhibiting virus replication in vitro. Journal of Immunology 136: 681–685, 1986Google Scholar
  77. Perkins R, Minchey SR, Boni LT, Swenson CE, Popescu MC, et al. Amphotericin B phospholipid interaction responsible for reduced mammalian cell toxicity, Biochimica et Biophysica Acta, in press, 1992Google Scholar
  78. Peyman GA, Schulman JA, Khoobehi B, Alkan HM, Tawakol ME, et al. Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine. Retina 9: 232–236, 1989PubMedCrossRefGoogle Scholar
  79. Presant CA, Blayney D, Proffitt RT, Turner AF, Williams LE, et al. Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes. Lancet 335: 1307–1309, 1990PubMedCrossRefGoogle Scholar
  80. Proffitt RT, Satorius A, Chiang S-M, Sullivan L, Adler-Moore J-P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 49–61, 1991PubMedCrossRefGoogle Scholar
  81. Rahman A. Antitumour activity of liposomal encapsulated doxorubicin in advanced breast cancer: phase II study. Journal of the National Cancer Institute 82: 1706, 1990aPubMedCrossRefGoogle Scholar
  82. Rahman A, Kessler A, More N, Sikic R, Rowden G, et al. Liposomal protection of adriamycin-induced cardiomyopathy in mice. Cancer Research 40: 1532–1537, 1980PubMedGoogle Scholar
  83. Rahman A, Treat J, Roe JK, Potkul LA, Alvord WG, et al. Phase I clinical trial and pharmacokinetic evaluation of liposomal encapsulated doxorubicin. Journal of Clinical Oncology 8: 1093–1100, 1990bPubMedGoogle Scholar
  84. Rahman A, Woolley PV, Treat J. A phase II trial of liposomeencapsulated doxorubicin in advanced measurable breast cancer. In Gregoriadis et al. (Eds) Liposomes in drug delivery, Harwood, Chur, 1993Google Scholar
  85. Rao VS, Peyman GA, Khoobehi B, Vangipuram S. Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis. International Ophthalmology 13: 181–185, 1989PubMedCrossRefGoogle Scholar
  86. Richardson VJ, Jeyasingh K, Jewkes RF, Ryman BR. Possible tumour localization of Tc 99m-labelled liposomes: effects of lipid composition, charge and liposomal size. Journal of Nuclear Medicine 19: 1049–1054, 1978PubMedGoogle Scholar
  87. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. Journal of Antimicrobial Chemotherapy 28 (Suppl. B): 83–91, 1991PubMedCrossRefGoogle Scholar
  88. Roerdink FH, Kroon AM (Eds). Drug carrier systems, Wiley, Chichester, 1989Google Scholar
  89. Ryan PJ, Davis MA, Degaeta LR, Wanda B, Melchoir D. Liposomes loaded with contrast material for image enhancement in computed tomography. Radiology 152; 759–762, 1984PubMedGoogle Scholar
  90. Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Investigative Ophthalmology and Visual Science 21: 220–227, 1982Google Scholar
  91. Schwendener RA, Wuthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese- and iron-DTPA-stearate liposomes as organ-specific contrast agents. Investigative Radiology 25: 922–932, 1990PubMedCrossRefGoogle Scholar
  92. Seltzer SE, Gregoriadis G, Dick R. Evaluation of the dehydration-rehydration method for production of contrast-carrying liposomes. Investigative Radiology 23: 131–138, 1988PubMedCrossRefGoogle Scholar
  93. Seltzer SE, Adams DF, Davis MA, Hessel SJ, Havron A, et al. Hepatic contrast agents for computed tomography: high atomic number paniculate material. Journal of Computer Assisted Tomography 5: 370–374, 1981PubMedCrossRefGoogle Scholar
  94. Seltzer SE, Davis MA, Adams DF, Shulkin PM, Landis WJ, et al. Liposomes carrying diatrazoate characterization of biophysical properties and imaging application. Investigative Radiology 19: 142–151, 1984PubMedCrossRefGoogle Scholar
  95. Senior J, Gregoriadis G. Is half-life of circulating small unilamellar liposomes determined by changes in their permeability?. FEBS Letters 145: 109–114, 1982PubMedCrossRefGoogle Scholar
  96. Senior J, Crawley JCW, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochimica et Biophysica Acta 839: 1–8, 1985PubMedCrossRefGoogle Scholar
  97. Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethyleneglycol)-coated vesicles. Biochimica et Biophysica Acta 1092: 77–82, 1991CrossRefGoogle Scholar
  98. Singh K, Mezei M. Liposomal ophthalmic drug delivery system. I. Ttrinocinolone acetamide. International Journal of Pharmaceutics 16: 339–344, 1983Google Scholar
  99. Singh K, Mezei M. Liposomal ophthalmic drug delivery system. II. Dihydrostreptomycin sulphate. International Journal of Pharmaceutics 19: P263–269, 1984CrossRefGoogle Scholar
  100. Smolin G, Ikumoto M, Feiler S, Concon D. Idoxuridine-liposomes therapy for herpes-simplex keratitis. American Journal of Ophthalmology 91: 220–225, 1981PubMedGoogle Scholar
  101. Stratford RE, Yang DC, Redell MA, Lee VHL. Effects of topically applied liposomes on disposition of epinephrine and inulin in the albino rabbit eye. International Journal of Pharmaceutics 13: 263–272, 1983CrossRefGoogle Scholar
  102. Swenson CE, Stewart KA, Hammett JL, Fitzsimmons WE, Ginsberg RS. Pharmacokinetics and in vivo activity of liposomeencapsulated gentamycin. Antimicrobial Agents and Chemotherapy 34: 235–240, 1990PubMedCrossRefGoogle Scholar
  103. Szoka FC. The macrophage as the principle antigen-presenting cell for liposome-encapsulated antigens, Research in Immunology 143: 186–187, 1992PubMedCrossRefGoogle Scholar
  104. Tan L, Gregoriadis G. The effect of interleukin-2 on the immunoadjuvant action of liposomes. Biochemical Society Transactions 17: 693–694, 1989Google Scholar
  105. Taylor RL, Williams PM, Draven PC, Graybile JR, Drutz DJ, et al. Amphotericin B in liposomes: a novel therapy for histoplasmosis. American Reviews of Respiratory Disease 125: 610–611, 1982Google Scholar
  106. Turner A, Kirby C, Senior J, Gregoriadis G. Fate of cholesterolrich unilamellar liposomes containing 111In-labelled bleomycin after subcutaneous injection into rats. Biochimica et Biophysica Acta 760: 119–125, 1983CrossRefGoogle Scholar
  107. Vincent M, Webster MH, Pether JVS. Liposomal amphotericin B. Lancet 339: 374–375, 1992PubMedCrossRefGoogle Scholar
  108. White C, Slifkin M, Seltzer SE, Blau M, Adzamli IK, et al. Biodistribution and clearance of contrast-carrying MREV liposomes. Investigative Radiology 25: 1125–1129, 1990PubMedCrossRefGoogle Scholar
  109. Yu BF. Preliminary clinical application of new bone marrow imaging agent 99mTc-polyphase liposomes in malignant lymphoma. Chung-Hua-Chung-Liu-Tsa-Chih 12: 297–300, 1990PubMedGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Gregory Gregoriadis
    • 1
  • Alexander T. Florence
    • 1
  1. 1.Centre for Drug Delivery Research, School of PharmacyUniversity of LondonLondonEngland

Personalised recommendations